SCHEMBL2841874

SCHEMBL2841874

O=Cc1cc(Nc2ccccc2)n(-c2ccccc2)n1.OCc1cc(Nc2ccccc2)n(-c2ccccc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.49
HPGD P15428 3/20 0.49
MAPK1 P28482 1/20 0.49
GFER P55789 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 1/20 0.43
MAPT P10636 1/20 0.41
RECQL P46063 1/20 0.41
KCNJ6 P48051 7/20 0.39
KCNJ5 P48544 7/20 0.39
KCNJ3 P48549 7/20 0.39
TSHR P16473 1/20 0.38
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
CA9 Q16790 3/20 0.38
PTGS2 P35354 1/20 0.38
MAPK13 O15264 1/20 0.37
MAPK12 P53778 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2839406 0.88 GAA (0.60) GAAHPGDMAPK1GFERSMN1; SMN2
SCHEMBL2841019 0.88 GAA (0.60) GAAHPGDMAPK1GFERSMN1; SMN2
SCHEMBL16780330 0.73 ALDH1A1 (0.59) GAASMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL10014879 0.72 CA9 (0.43) GAAALDH1A1LMNAMAPTCA1
SCHEMBL2840465 0.72 GAA (0.53) GAAHPGDMAPK1GFERSMN1; SMN2
SCHEMBL28210277 0.71 ALDH1A1 (0.50) GAASMN1; SMN2ALDH1A1LMNAHTT
Hydrochloric Acid SCHEMBL2839560 0.71 GAA (0.60) GAAHPGDMAPK1GFERSMN1; SMN2
SCHEMBL2835908 0.70 GAA (0.67) GAALMNA
SCHEMBL2837900 0.70 GAA (0.67) GAAALDH1A1LMNA
SCHEMBL2837826 0.69 ALDH1A1 (0.57) ALDH1A1LMNATSHRCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3162798-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-05-03 EP disclosed
EP-2196459-B1 5-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-11-02 EP disclosed
US-8334301-B2 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-18 US disclosed
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-19 US disclosed
EP-2196459-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND NPY4R, NPY5R, NPY1R GAA 1513/4885HPGD 138/4885MAPK1 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.